Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 5651903, 6 pages
https://doi.org/10.1155/2017/5651903
Review Article

Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions

Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-von-Guericke Universität, Leipziger Str. 44, 39120 Magdeburg, Germany

Correspondence should be addressed to Marino Venerito; ed.ugvo.dem@otirenev.m

Received 4 May 2017; Revised 7 June 2017; Accepted 27 June 2017; Published 13 July 2017

Academic Editor: Haruhiko Sugimura

Copyright © 2017 Katrin Bose et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11, International Agency for Research on Cancer, Lyon, France, 2014, http://www.globocan.iarc.fr.
  2. M. Venerito, A. Link, T. Rokkas, and P. Malfertheiner, “Gastric cancer - clinical and epidemiological aspects,” Helicobacter, vol. 21, Supplement 1, pp. 39–44, 2016, Review. View at Publisher · View at Google Scholar · View at Scopus
  3. E. C. Smyth, M. Verheij, W. Allum et al., “Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 27, Supplement 5, pp. v38–v49, 2016. View at Google Scholar
  4. N. Howlader, A. Noone, M. Krapcho et al., SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD, 2011.
  5. World Cancer Research Fund International/American Institute for Cancer Research, “Continuous update project report: diet, nutrition, physical activity and stomach cancer,” 2016, http://wcrf.org/stomach-cancer-2016.
  6. D. Forman and V. J. Burley, “Gastric cancer: global pattern of the disease and an overview of environmental risk factors,” Best Practice & Research. Clinical Gastroenterology, vol. 20, pp. 633–649, 2006. View at Google Scholar
  7. M. Venerito and P. Malfertheiner, “Preneoplastic conditions in the stomach: always a point of no return?” Digestive Diseases, vol. 33, no. 1, pp. 5–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Fischbach, P. Malfertheiner, P. Lynen Jansen et al., “S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease,” Zeitschrift für Gastroenterologie, vol. 54, no. 4, p. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Plummer, S. Franceschi, J. Vignat, D. Forman, and C. Martel, “Global burden of gastric cancer attributable to pylori,” International Journal of Cancer, vol. 136, pp. 487–490, 2015. View at Google Scholar
  10. M. Venerito, R. Vasapolli, and P. Malfertheiner, “Prevention, early diagnosis and therapy of gastric cancer,” MMW Fortschritte der Medizin, vol. 158, no. 13, pp. 39–43, 2016. View at Publisher · View at Google Scholar
  11. M. Venerito, E. Goni, and P. Malfertheiner, “Helicobacter pylori screening: options and challenges,” Expert Review of Gastroenterology & Hepatology, vol. 10, no. 4, pp. 497–503, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11, International Agency for Research on Cancer, Lyon, France, 2015.
  13. M. Venerito, C. Helmke, D. Jechorek et al., “Leukotriene receptor expression in esophageal squamous cell cancer and non-transformed esophageal epithelium: a matched case control study,” BMC Gastroenterology, vol. 16, no. 1, p. 85, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. A. A. Botterweck, L. J. Schouten, A. Volovics, E. Dorant, and P. A. Brandt, “Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries,” International Journal of Epidemiology, vol. 29, pp. 645–654, 2000. View at Google Scholar
  15. “Cancer of the oesophagus—SEER stat fact sheets,” April 2007, https://seer.cancer.gov/statfacts/html/esoph.html.
  16. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet‐Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, pp. 87–108, 2015. View at Google Scholar
  17. J. Bornschein, A. Dingwerth, M. Selgrad et al., “Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions,” European Journal of Gastroenterology & Hepatology, vol. 27, no. 5, pp. 492–500, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Cunningham, W. H. Allum, S. P. Stenning et al., “Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” The New England Journal of Medicine, vol. 355, pp. 11–20, 2006. View at Google Scholar
  19. M. Ychou, V. Boige, J. P. Pignon et al., “Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial,” Journal of Clinical Oncology, vol. 29, pp. 1715–1721, 2011. View at Google Scholar
  20. D. Alderson, R. E. Langley, M. G. Nankivell et al., “Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072),” American Society of Clinical Oncology, vol. 33, no. 15s, 2015. View at Google Scholar
  21. S. Lorenzen, D. Arnold, C. Fottner et al., “ASCO-update 2015 – Neuigkeiten vom 51. Meeting der American Society of Clinical Oncology/ASCO 2015. ASCO-update 2015 – highlights of the 51. Meeting of the American Society of Clinical Oncology/ASCO 2015,” Zeitschrift für Gastroenterologie, vol. 54, pp. 167–172, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. S. E. Al-Batran, R. D. Hofheinz, C. Pauligk et al., “Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial,” The Lancet Oncology, vol. 17, no. 12, pp. 1697–1708, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. “5-FU, leucovorin, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric cancer,” April 2017, https://clinicaltrials.gov/ct2/show/NCT01216644 last updated and last verified march 2017.
  24. S. E. Al-Batran, N. Homann, H. Schmalenberg et al., “Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial,” Journal of Clinical Oncology, vol. 35, Supplement 15, p. 4004, 2017. View at Google Scholar
  25. F. Lordick, C. Mariette, K. Haustermans, R. Obermannová, D. Arnold, and ESMO Guidelines Committee, “Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 27, Supplement 5, pp. v50–v57, 2016. View at Google Scholar
  26. D. Cunningham, N. Starling, S. Rao et al., “Capecitabine and oxaliplatin for advanced esophagogastric cancer,” The New England Journal of Medicine, vol. 358, pp. 36–46, 2008. View at Google Scholar
  27. J. A. Ajani, M. Buyse, M. Lichinitser et al., “Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the first-line advanced gastric cancer study,” European Journal of Cancer, vol. 49, no. 17, pp. 3616–3624, 2013. View at Google Scholar
  28. C. Franck, P. Malfertheiner, and M. Venerito, “Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer,” BML Case Reports, 2017. View at Publisher · View at Google Scholar
  29. T. Aoyama, K. Nishikawa, K. Fujitani et al., “Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer,” Annals of Oncology, 2017. View at Publisher · View at Google Scholar
  30. S.-E. Al-Batran and G. zur Hausen, “NCT02581462 - FLOT vs. FLOT/herceptin/pertuzumab for perioperative therapy of adenocarcinoma of the stomach and gastroesophageal junction expressing HER-2. A phase II/III trial of the AIO,” ClinicalTrials.gov 2016 [cited 2017 Apr 23] https://clinicaltrials.gov/ct2/show/NCT02581462.
  31. Y. J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial,” Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. D. Wagner, “NCT02205047 - neoadjuvant study using trastuzumab or trastuzumab with pertuzumab in gastric or gastroesophageal junction adenocarcinoma (INNOVATION),” ClinicalTrials.gov 2016 [cited 2017 Apr 23]; https://clinicaltrials.gov/ct2/show/NCT02205047.
  33. D. Cunningham, S. P. Stenning, E. C. Smyth et al., “Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial,” The Lancet Oncology, vol. 18, pp. 357–370, 2017. View at Google Scholar
  34. S.-E. Al-Batran and U. S. Bankstahl, “NCT02661971 - perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma - RAMSES - a phase II/III trial of the AIO,” ClinicalTrials.gov 2017 [cited 2017 Apr 23]; https://clinicaltrials.gov/ct2/show/NCT02661971.
  35. W. Sun, “NCT02943603 - a study of perioperative mFOLFOX6 plus pembrolizumab in patients with potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ) and stomach,” ClinicalTrials.gov 2016 [cited 2017 Apr 23]; https://clinicaltrials.gov/ct2/show/NCT02943603.
  36. D. Otap, M. Shah, and P. Oberstein, “NCT02918162 - perioperative chemo and pembrolizumab in gastric cancer,” ClinicalTrials.gov 2017 [cited 2017 Apr 23]; https://clinicaltrials.gov/ct2/show/NCT02918162.
  37. G. H. Mickisch, A. Garin, H. Poppel, L. Prijck, R. Sylvester, and for the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group, “Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial,” Lancet, vol. 358, pp. 966–970, 2001. View at Google Scholar
  38. R. C. Flanigan, S. E. Salmon, B. A. Blumenstein et al., “Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer,” The New England Journal of Medicine, vol. 345, pp. 1655–1659, 2001. View at Google Scholar
  39. K. Fujitani, H.-K. Yang, J. Mizusawa et al., “Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial,” The Lancet Oncology, vol. 17, pp. 309–318, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. “ClinicalTrials.gov Identifier: NCT02578368,” https://clinicaltrials.gov/ct2/show/NCT02578368.
  41. S. E. Al-Batran, N. Homann, C. Pauligk et al., “Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial,” JAMA Oncology, 2017. View at Publisher · View at Google Scholar
  42. E. C. Smyth, M. Fassan, D. Cunningham et al., “Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial,” Journal of Clinical Oncology, vol. 34, no. 23, pp. 2721–2727, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Mandard, F. Dalibard, J. C. Mandard et al., “Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations,” Cancer, vol. 73, no. 11, pp. 2680–2686, 1994. View at Google Scholar
  44. T. Schmidt, L. Sicic, S. Blank et al., “Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas,” British Journal of Cancer, vol. 110, no. 7, pp. 1712–1720, 2014. View at Google Scholar
  45. S. Y. Kim, Y. Y. Choi, J. Y. An et al., “The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses,” International Journal of Cancer, vol. 137, pp. 819–825, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. E. C. Smyth, A. Wotherspoon, C. Peckitt et al., “Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial,” JAMA Oncology, 2017. View at Publisher · View at Google Scholar